Our current study demonstrates for the first time that IL-22 and ILC3s can prevent excess inflammation and clear Mtb infection in T2DM and TB comorbid conditions, suggesting that IL-22 is a novel target for treating TB patients with T2DM. Here, IL22 is linked to type 2 diabetes mellitus.